Shield Therapeutics plc
Shield Therapeutics plc, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on developing innovative therapies for iron deficiency and related conditions. Founded in 2013, the company has made significant strides in the industry, particularly with its flagship product, Accrufer® (ferric maltol), which offers a unique oral treatment option for patients with iron deficiency anaemia. With a strong presence in both the UK and the US markets, Shield Therapeutics is committed to addressing unmet medical needs through its advanced formulations. The company has achieved notable milestones, including successful regulatory approvals and partnerships that enhance its market position. By prioritising patient-centric solutions, Shield Therapeutics continues to set itself apart in the biopharmaceutical landscape, driving advancements in iron therapy.
DitchCarbon Score
How does Shield Therapeutics plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shield Therapeutics plc's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shield Therapeutics plc's reported carbon emissions
Shield Therapeutics plc, headquartered in Great Britain, currently does not have any publicly available carbon emissions data for the most recent year, nor do they have specified reduction targets or climate commitments outlined. Without specific emissions figures or reduction initiatives, it is unclear how the company is addressing its carbon footprint or contributing to climate action within the pharmaceutical industry. As the industry increasingly focuses on sustainability, it is essential for companies like Shield Therapeutics to establish clear climate commitments and measurable targets to enhance their environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shield Therapeutics plc is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
